Evidence map›Paper›PMID 35205786›Full record

ArticleCancers2022

Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study).

Ylva Naeser, Hildur Helgadottir, Johan Hansson, Christian Ingvar, Nils O Elander, Petra Flygare, Cecilia Nilsson, Frida Jakobsson, Antonios Valachis, Dimitrios Papantoniou and 5 more

Abstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ylva NaeserRudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0003-3628-4538
Hildur HelgadottirDepartment of Oncology-Pathology, Karolinska Institutet, 171 77 Stockholm, Sweden.
Johan HanssonTheme Cancer, Karolinska University Hospital, 171 76 Stockholm, Sweden.
Christian IngvarDepartment of Surgery, Clinical Sciences, Lund University, BMC F12, 221 84 Lund, Sweden.ORCID 0000-0002-7721-4619
Nils O ElanderDepartment of Biomedical and Clinical Sciences, Linköping University, 581 85 Linköping, Sweden.
Petra FlygareDepartment of Oncology, Sundsvall County Hospital, Lasarettsgatan 21, 856 43 Sundsvall, Sweden.
Cecilia NilssonDepartment of Oncology, Hospital of Västmanland Västerås, 721 89 Västerås, Sweden.
Frida JakobssonDepartment of Oncology, Örebro University Hospital, 701 85 Örebro, Sweden.
Antonios ValachisDepartment of Oncology, Faculty of Medicine and Health, Örebro University, 701 82 Örebro, Sweden.
Dimitrios PapantoniouDepartment of Oncology, Ryhov County Hospital, 551 85 Jönköping, Sweden.ORCID 0000-0002-5966-8879
Agneta Nordin DanforsDepartment of Oncology, Visby County Hospital, St. Göransgatan 5, 621 84 Visby, Sweden.
Hemming JohanssonDepartment of Oncology-Pathology, Karolinska Institutet, 171 77 Stockholm, Sweden.
Anders SundinDepartment of Surgical Sciences Radiology & Molecular Imaging, Uppsala University, 751 85 Uppsala, Sweden.
Yvonne BrandbergDepartment of Oncology-Pathology, Karolinska Institutet, 171 77 Stockholm, Sweden.
Gustav J UllenhagRudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0003-4949-3267

Funding

Lion´s Cancer fund Not applicableStiftelsen Onkologiska Klinikens i Uppsala Forskningsfond Not applicable
6 · The paper itself

Abstract

The benefit of imaging in the follow-up setting for high-risk melanoma patients is uncertain, and even less is known about the impact of intensive follow-up on the patient´s quality of life. In 2017, a Swedish prospective randomized multicenter study started, in which high-risk melanoma patients are randomly assigned 1:1 to follow-up by physical examinations +/- whole-body imaging. The first-year examinations are scheduled at 0, 6 and 12 months. The aim of this study was to investigate whether the patients´ health-related quality of life (HRQoL) and levels of anxiety and depression were affected at 1 year by imaging. Anxiety/depression and HRQoL were assessed at 0 and 12 months by the questionnaires Hospital Anxiety and Depression (HAD) scale and EORTC QLQ-C30 version 3. Expected baseline QLQ-C30 values for the patients were calculated using data from the general population. In total, 204 patients were analyzed. Mean differences in subscale scores at 1 year were not statistically significant either for HRQoL or for anxiety/depression. Baseline HRQoL did not differ from expected values in the general Swedish population. In conclusion, the patients in general coped well with the situation, and adding whole-body imaging to physical examinations did not affect the melanoma patients' HRQoL or levels of anxiety or depression.

Indexed as

follow-up studiesmelanomapositron emission tomography computed tomographyprospective studiesquality of liferandomized controlled trialtomographyX-ray computed

Identifiers

PMID35205786
PMCPMC8869964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.